Core Viewpoint - Nomura forecasts that JD Health's performance in the second half of 2025 will exceed market expectations, primarily driven by a surge in flu cases in the fourth quarter, leading to increased demand for pharmaceuticals [1] Revenue Projections - Nomura estimates that JD Health's revenue in the fourth quarter of 2025 will reach 20 billion yuan, representing a year-on-year growth of 22% [1] - The growth is attributed to the pharmaceutical, nutritional, and medical device segments, which are expected to achieve year-on-year sales growth of 30%, 20%, and 10% respectively [1] Market Drivers - The spread of flu cases in the fourth quarter is expected to significantly contribute to pharmaceutical sales, accounting for a high single-digit percentage of total pharmaceutical revenue [1] - Sales of medical devices, such as home oxygen concentrators, are also anticipated to increase due to the flu outbreak [1] Marketing Strategies - Nutritional brands are expected to continue effective marketing campaigns in the fourth quarter, reinforcing their robust growth trajectory [1]

Core Viewpoint - CICC has raised JD Health's revenue forecasts for 2025 and 2026 by 2% to 72.5 billion yuan and 81.7 billion yuan respectively, driven by the ongoing growth of original drug categories and strong demand for flu products [1] Group 1: Revenue Performance - The company is expected to show strong revenue growth, with a projected year-on-year increase of nearly 25% for the entire year of 2025, supported by the continuous release of original drugs and the rising demand for flu prevention since Q4 2025 [2] - In the first three quarters of 2025, the company achieved a quarterly revenue growth rate of approximately 25% year-on-year [2] Group 2: Profitability Outlook - The company's non-IFRS net profit margins for the first three quarters of 2025 were 10.6%, 9.7%, and 11.1%, showing varying degrees of improvement year-on-year, primarily due to increased advertising and marketing investments by pharmaceutical and health product companies [3] - Despite the typical increase in expenditures during Q4 2025, the company is expected to maintain a stable profit margin for the year, reflecting strong competitive capabilities [3] - The company has significant cash reserves, and potential fluctuations in interest income due to interest rate cuts may impact non-IFRS net profit in the coming quarters [3]

Group 1 - The core viewpoint is that JD Health's revenue forecasts for 2025 and 2026 have been raised by 2% to 72.5 billion and 81.7 billion respectively, driven by the strong demand for flu products and the ongoing trend of original research products [1] - The company is expected to achieve a year-on-year revenue growth of approximately 25% in 2025, with strong quarterly performance observed in the first three quarters [2] - The non-IFRS net profit for 2025 and 2026 has been adjusted upwards by 4% and 1% to 6.5 billion and 6.4 billion respectively, with a new revenue forecast for 2027 set at 91.2 billion and non-IFRS net profit at 6.8 billion [1] Group 2 - The company has shown a steady improvement in non-IFRS net profit margins, with rates of 10.6%, 9.7%, and 11.1% in the first three quarters of 2025, attributed to increased marketing investments by pharmaceutical and health product companies [3] - Despite the potential fluctuations in interest income due to cash management strategies, the overall profit performance is expected to remain robust, reflecting the company's strong competitive position [3] - The company has signed strategic cooperation agreements with major pharmaceutical firms, enhancing its business model for new drug launches [2]

Core Insights - The demand for health supplements, particularly ginseng, has surged during the New Year holiday, with sales increasing by 55% year-on-year according to JD Health's data [1] - JD Health has established a "one ginseng, one certificate" quality traceability system, allowing consumers to verify product origins, growth years, and testing results through QR codes [1][3] Group 1: Industry Overview - Jilin Province is recognized as the original and core production area for ginseng in China, benefiting from unique ecological conditions and extensive cultivation experience [3] - The province has developed a comprehensive ginseng industry system that integrates planting, processing, and research, positioning itself as a key player in the global ginseng market [3] - JD Health is collaborating with Jilin Province to enhance the ginseng industry from a resource advantage to a brand and value advantage, promoting high-quality, traceable ginseng products [3] Group 2: Product Standards and Quality Control - In 2023, JD Health, in collaboration with authoritative institutions, launched the "JD Good Ginseng" standards, which set clear and strict requirements for ginseng definition, age labeling, and testing certification, exceeding national standards in some areas [3] - JD Health applies rigorous quality control and traceability systems to both everyday health supplements and high-grade, rare ginseng resources, ensuring a regulated display and certification environment [4] - A notable auction of a century-old wild ginseng from Changbai Mountain showcased a specimen weighing 123 grams, surpassing national standards for premium wild ginseng [4] Group 3: Future Developments - JD Health plans to continue enhancing its quality control standards and traceability systems while deepening collaboration with local governments and industry in Jilin Province to promote standardized, transparent, and scalable development of health supplements [5]

京东健康(06618)发布公告，于2026年1月1日，公司根据首次公开发售后股份奖励计划向承授人授出了 涉及53.65万股新股份的53.65万股奖励股份，约占于授出日期已发行股份总数的0.02%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） 授出股份獎勵 董事會宣佈，於2026年1月1日，本公司根據首次公開發售後股份獎勵計劃向承授人授出 了涉及536,489股新股份的536,489股獎勵股份，約佔於授出日期已發行股份總數的0.02%。 授出的詳情如下： (iii) 86,560股獎勵股份將於授出日期起1至4年內歸屬。 授出74,078股獎勵股份的歸屬期間少於12個月，原因為該 等股份為出於行政管理原因在一年內分批授出的部分獎 勵。 1 授出日期： 2026年1月1日 承授人： 本集團僱員（不包括本集團董事及高級管理人員） 授出的對價： 零 授出獎勵股份的數目： 536,489股 授出日期股份的市價： 每股55.500港元 （附註） 歸屬期間： (i) 61,494股獎勵 ...

Group 1 - The core viewpoint of the news is the online launch of the innovative oral antiviral drug, Mapasavir Capsules (brand name: Yilikang®), by Health元药业集团 on JD Health platform, aimed at providing a new treatment option for influenza [1][3]. - Influenza, caused by the influenza virus, poses a significant health threat, especially to vulnerable populations such as children, the elderly, and those with chronic diseases, necessitating timely antiviral treatment to mitigate risks [3]. - Mapasavir Capsules utilize a novel mechanism as a cap-dependent endonuclease inhibitor, effectively blocking the replication of the influenza virus at an early stage, offering broad-spectrum antiviral activity against both type A and B influenza viruses [3]. Group 2 - Health元药业集团 is an innovative pharmaceutical group focused on unmet clinical needs, with over 20 first-class innovative drugs in its portfolio, more than 10 of which are in critical phases of development [4]. - The online launch of Yilikang® marks the beginning of a deeper collaboration between Health元 and JD Health, leveraging JD Health's marketing resources and supply chain to enhance patient access to the drug [4]. - Future collaborations will focus on comprehensive influenza prevention and treatment, including improving drug accessibility, patient education, and influenza warning systems, aiming to create an integrated health service ecosystem [4].

Core Insights - JD Health and Nanchang University First Affiliated Hospital have signed a strategic cooperation framework agreement to leverage opportunities in "Artificial Intelligence + Healthcare" [1][3] - The collaboration aims to enhance patient service experience and hospital operational capabilities through the integration of JD Health's "JD Zhuoyi" large model product [1][3] Group 1: Strategic Collaboration - The partnership will create an integrated patient service entry point covering pre-diagnosis, diagnosis, and post-diagnosis processes, improving patient experience [3] - A comprehensive nutrition management system will be established, forming a closed-loop management system from risk screening to clinical intervention and consumer conversion [3] Group 2: Technological Integration - JD Health will utilize its e-commerce platform, pharmaceutical supply chain, logistics, and digital marketing capabilities to support the hospital's internal products and services [4] - The collaboration will also establish a convenient health service platform that includes online health services and offline self-service vending machines to meet patient needs throughout their healthcare journey [4] Group 3: Industry Impact - The strategic cooperation is seen as a significant step in applying "Artificial Intelligence + Healthcare" in practice, setting a benchmark for the industry [4] - JD Health aims to continuously enhance patient medical experience and contribute to the high-quality development of the healthcare industry through innovative products and services [4]

近日，京东健康与南昌大学第一附属医院(以下简称"南大一附院")正式签署战略合作框架协议。双方将 把握"人工智能+医疗健康"发展机遇，依托京东健康面向医院全场景打造的大模型产品"京东卓医"，以 一体化管理为基础、以优质医疗资源下沉共享为核心，助力南大一附院构建以患者为核心、线上线下全 流程一体化的医疗服务新模式，切实提升患者服务体验。 作为全国首批三级甲等医院，南大一附院承担着江西省重大公共卫生事件医学中心、国家重大疫情防控 救治基地等重要职能，在医疗资源配置、临床诊疗能力和行业影响力方面具备雄厚实力。作为行业领先 的新型医疗健康服务机构，京东健康依托"京东卓医"大模型产品，助力多家线下医疗机构提供更加高 效、普惠、智能的医疗健康服务。此次双方的战略合作，正是响应国家政策导向、顺应行业发展趋势的 重要实践。 根据合作协议，双方将基于"京东卓医"大模型产品，共同构建一体化患者服务主入口，覆盖诊前、诊 中、诊后全流程场景，提升患者服务体验与医院经营能力。双方将合作建立营养全程管理体系，构 建"筛-评-诊-治-管"临床营养一体化系统，形成"风险筛查-临床干预-消费转化"闭环管理。同时，整合南 大一附院检验科专业能力和 ...

近年来，中医药滋补养生市场持续扩容。其中，六味地黄类产品作为滋阴补肾的经典品类，市场需求潜 力巨大。与此同时，传统剂型正加速向更便捷、更适口的方向创新，膏滋、口服液等新剂型日益受到当 代快节奏生活人群的青睐。华润江中敏锐洞察这一趋势，将传承千年的经典名方与现代剂型创新相结 合，为滋阴补肾市场带来一款易于服用、方便携带、高效吸收的膏滋新品，满足现代消费者对高效、便 捷、品质滋补的新需求。 12月25日，华润江中旗下六味地黄膏在京东健康首发上线，消费者即日起登录京东APP搜索"江中六味 地黄膏"即可咨询与购买，开启轻松、便捷的滋补调理新体验。 作为国民信赖的健康品牌，华润江中始于1969年，是一家集医药研发、生产与销售于一体的国有大型企 业，旗下"江中"品牌价值超466亿元，已连续22年入选中国500最具价值品牌。其位于南昌的江中药谷制 造基地，是国家级绿色工厂与智能制造的典范。2023年，华润江中牵头获批"经典名方现代中药创制全 国重点实验室"，依托4个国家级及8个省部级研发平台，构建了从药材源头到产品出厂的全链条质量管 控体系，为六味地黄膏等产品的卓越品质保驾护航。 本次新品发布是双方深度合作的又一重要里程碑 ...